Presentation highlights results from 13- and 39-week studies of eneboparatide in non-human primates demonstrating no evidence of deleterious impact on bone quantity or quality as measured by multiple bone
LYON, France and CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced